Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'Fleischhacker, WW' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 96 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Holzner, B; Kemmler, G; Sperner-Unterweger, B; Kopp, M; Dunser, M; Margreiter, R; Marschitz, I; Nachbaur, D; Fleischhacker, WW; Greil, R
      Quality of life measurement in oncology - a matter of the assessment instrument?

      EUROPEAN JOURNAL OF CANCER
    2. Moschen, R; Kemmler, G; Schweigkofler, H; Holzner, B; Dunser, M; Richter, R; Fleischhacker, WW; Sperner-Unterweger, B
      Use of alternative/complementary therapy in breast cancer patients - a psychological perspective

      SUPPORTIVE CARE IN CANCER
    3. Marksteiner, J; Weiss, U; Weis, C; Laslop, A; Fischer-Colbrie, R; Humpel, C; Feldon, J; Fleischhacker, WW
      Differential regulation of chromogranin A, chromogranin B and secretogranin II in rat brain by phencyclidine treatment

      NEUROSCIENCE
    4. Fleischhacker, WW; Lemmens, P; van Baelen, B
      A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database

      PHARMACOPSYCHIATRY
    5. Meltzer, HY; Fleischhacker, WW
      Weight gain: A growing problem in schizophrenia management

      JOURNAL OF CLINICAL PSYCHIATRY
    6. Kurzthaler, I; Fleischhacker, WW
      The clinical implications of weight gain in schizophrenia

      JOURNAL OF CLINICAL PSYCHIATRY
    7. Holzner, B; Kemmler, G; Kopp, M; Moschen, R; Schweigkofler, H; Dunser, M; Margreiter, R; Fleischhacker, WW; Sperner-Unterweger, B
      Quality of life in breast cancer patients - Not enough attention for long-term survivors?

      PSYCHOSOMATICS
    8. Bodner, T; Jenner, C; Benke, T; Ober, A; Seppi, K; Fleischhacker, WW
      Intoxication with riluzole in Huntington's disease

      NEUROLOGY
    9. Eder, U; Mangweth, B; Ebenbichler, C; Weiss, E; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Fleischhacker, WW
      Association of olanzapine-induced weight gain with an increase in body fat

      AMERICAN JOURNAL OF PSYCHIATRY
    10. Hausmann, A; Fleischhacker, WW
      Depression in patients with schizophrenia - Prevalence, and diagnostic andtreatment considerations

      CNS DRUGS
    11. Fleischhacker, WW
      Methodological challenges in the clinical development of antipsychotic drugs

      CURRENT OPINION IN PSYCHIATRY
    12. Kopp, M; Schweigkofler, H; Holzner, B; Nachbaur, D; Niederwieser, D; Fleischhacker, WW; Kemmler, G; Sperner-Unterwerger, B
      EORTC QLQ-C30 and FACT-BMT for the measurement of quality of life in bone marrow transplant recipients: a comparison

      EUROPEAN JOURNAL OF HAEMATOLOGY
    13. Bauer, R; Mayr, A; Lederer, W; Needham, PL; Kilpatrick, IC; Fleischhacker, WW; Marksteiner, J
      Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs

      NEUROPSYCHOPHARMACOLOGY
    14. Weiss, E; Hummer, M; Koller, D; Ulmer, H; Fleischhacker, WW
      Off-label use of antipsychotic drugs

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    15. Hofer, A; Hummer, M; Huber, R; Kurz, M; Walch, T; Fleischhacker, WW
      Selection bias in clinical trials with antipsychotics

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    16. Deisenhammer, EA; Whitworth, AB; Geretsegger, C; Kurzthaler, I; Gritsch, S; Miller, CH; Fleischhacker, WW; Stuppack, CH
      Intravenous versus oral administration of amitriptyline in patients with major depression

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    17. Miller, CH; Fleischhacker, WW
      Managing antipsychotic-induced acute and chronic akathisia

      DRUG SAFETY
    18. Deisenhammer, EA; DeCol, C; Honeder, M; Hinterhuber, H; Fleischhacker, WW
      In-patient suicide in psychiatric hospitals

      ACTA PSYCHIATRICA SCANDINAVICA
    19. Oehl, M; Hummer, M; Fleischhacker, WW
      Compliance with antipsychotic treatment

      ACTA PSYCHIATRICA SCANDINAVICA
    20. Fleischhacker, WW; Marksteiner, J
      Future perspectives in antipsychotic drug development

      NEUROTRANSMITTER RECEPTORS IN ACTIONS OF ANTIPSYCHOTIC MEDICATIONS
    21. Fleischhacker, WW
      The psychopharmacology of schizophrenia

      CURRENT OPINION IN PSYCHIATRY
    22. Sperner-Unterweger, E; Miller, C; Holzner, B; Widner, B; Fleischhacker, WW; Fuchs, D
      Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients

      PSYCHIATRY, PSYCHOIMMUNOLOGY, AND VIRUSES
    23. Sperner-Unterweger, B; Whitworth, A; Kemmler, G; Hilbe, W; Thaler, J; Weiss, G; Fleischhacker, WW
      T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients

      SCHIZOPHRENIA RESEARCH
    24. Fleischhacker, WW; Hummer, M
      Do phase III trials have clinical value?

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    25. Kurzthaler, I; Hummer, M; Miller, C; Sperner-Unterweger, B; Gunther, V; Wechdorn, H; Battista, HJ; Fleischhacker, WW
      Effect of cannabis use on cognitive functions and driving ability

      JOURNAL OF CLINICAL PSYCHIATRY
    26. Fleischhacker, WW
      Clozapine: A comparison with other novel antipsychotics

      JOURNAL OF CLINICAL PSYCHIATRY
    27. Hummer, M; Kemmler, G; Kurz, M; Kurzthaler, I; Oberbauer, H; Fleischhacker, WW
      Sexual disturbances during clozapine and haloperidol treatment for schizophrenia

      AMERICAN JOURNAL OF PSYCHIATRY
    28. Fleischhacker, WW
      Untitled

      ACTA PSYCHIATRICA SCANDINAVICA
    29. KOPP M; SCHWEIGKOFLER H; HOLZNER B; NACHBAUR D; NIEDERWIESER D; FLEISCHHACKER WW; SPERNERUNTERWEGER B
      TIME AFTER BONE-MARROW TRANSPLANTATION AS AN IMPORTANT VARIABLE FOR QUALITY-OF-LIFE - RESULTS OF A CROSS-SECTIONAL INVESTIGATION USING 2 DIFFERENT INSTRUMENTS FOR QUALITY-OF-LIFE ASSESSMENT

      Annals of hematology
    30. KANE JM; AGUGLIA E; ALTAMURA AC; GUTIERREZ JLA; BRUNELLO N; FLEISCHHACKER WW; GAEBEL W; GERLACH J; GUELFI JD; KISSLING W; LAPIERRE YD; LINDSTROM E; MENDLEWICZ J; RACAGNI G; CARULLA LS; SCHOOLER NR
      GUIDELINES FOR DEPOT ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIA

      European neuropsychopharmacology
    31. WHITWORTH AB; HONEDER M; KREMSER C; KEMMLER G; FELBER S; HAUSMANN A; WANKO C; WECHDORN H; AICHNER F; STUPPAECK C; FLEISCHHACKER WW
      HIPPOCAMPAL VOLUME REDUCTION IN MALE-SCHIZOPHRENIC PATIENTS

      Schizophrenia research
    32. HONEDER M; WHITWORTH AB; KEMMLER G; KREMSER C; FELBER S; WECHDORN H; HAUSMANN A; WANKO C; STUPPACK CH; FLEISCHHACKER WW
      MRI VOLUMETRIC FOLLOW-UP-STUDY OF SCHIZOPHRENIC-PATIENTS

      Schizophrenia research
    33. KURZ M; HAUSMANN A; HONEDER M; KEMMLER G; KURZTHALER I; WALCH T; WECHDORN H; FLEISCHHACKER WW
      CHANGES IN PSYCHOPHARMACOLOGICAL TREATMENT STRATEGIES IN SCHIZOPHRENIA - INPATIENT TREATMENT 1989 VS. 1995

      Schizophrenia research
    34. HUMMER M; KOLLER D; HOFER A; ULMER H; FLEISCHHACKER WW
      OFF-LABEL USE OF ANTIPSYCHOTIC-DRUGS

      Schizophrenia research
    35. EDER U; KOLLER D; HUMMER M; KURZTHALER I; ULMER H; FLEISCHHACKER WW
      VARIABLES INFLUENCING OUTPATIENTS COMPLIANCE

      Schizophrenia research
    36. WEISS E; DANZL C; HUMMER M; KEMMLER G; LINDNER C; REINSTADLER K; FLEISCHHACKER WW
      WEIGHT-GAIN INDUCED BY OLANZAPINE

      Schizophrenia research
    37. FLEISCHHACKER WW; HAFNER H; LEFF J; LOPEZIBOR JJ; MAJ M; SARTORIUS N; STEFANIS CN; WARNER R; WIG NN
      THE WPA GLOBAL PROGRAM AGAINST STIGMA AND DISCRIMINATION BECAUSE OF SCHIZOPHRENIA

      Schizophrenia research
    38. MILLER CH; MOHR F; UMBRICHT D; WOERNER M; FLEISCHHACKER WW; LIEBERMAN JA
      THE PREVALENCE OF ACUTE EXTRAPYRAMIDAL SIGNS AND SYMPTOMS IN PATIENTSTREATED WITH CLOZAPINE, RISPERIDONE, AND CONVENTIONAL ANTIPSYCHOTICS

      The Journal of clinical psychiatry
    39. KURZ M; HUMMER M; KEMMLER G; KURZTHALER I; SARIA A; FLEISCHHACKER WW
      LONG-TERM PHARMACOKINETICS OF CLOZAPINE

      British Journal of Psychiatry
    40. SPERNERUNTERWEGER B; CZEIPEK I; GAGGL S; GEISSLER D; SPIEL G; FLEISCHHACKER WW
      TREATMENT OF SEVERE CLOZAPINE-INDUCED NEUTROPENIA WITH GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) - REMISSION DESPITE CONTINUOUS TREATMENT WITH CLOZAPINE

      British Journal of Psychiatry
    41. KOPP M; SCHWEIGKOFLER H; HOLZNER B; NACHBAUER D; NIEDERWIESER D; FLEISCHHACKER WW; SPERNERUNTERWEGER B
      COMPARISON OF 2 INSTRUMENTS FOR THE MEASUREMENT OF QUALITY-OF-LIFE INBONE-MARROW TRANSPLANTATION - EORTC QLQ-C30 VERSUS FACT-BMT

      Quality of life research
    42. SPERNERUNTERWEGER B; KEMMLER J; HOLZNER B; KOPP M; GREIL R; MARGREITER M; FLEISCHHACKER WW
      ASSESSMENT OF QUALITY-OF-LIFE IN ONCOLOGY - A COMPARISON BETWEEN 2 DIFFERENT QUESTIONNAIRES

      Quality of life research
    43. MILLER CH; HUMMER M; OBERBAUER H; KURZTHALER I; DECOL C; FLEISCHHACKER WW
      RISK-FACTORS FOR THE DEVELOPMENT OF NEUROLEPTIC-INDUCED AKATHISIA

      European neuropsychopharmacology
    44. HUMMER M; KURZ M; KOHL C; WALCH T; FLEISCHHACKER WW
      SELECTION BIAS IN CLINICAL-TRIALS WITH ANTIPSYCHOTICS

      Schizophrenia research
    45. MILLER CH; MOHR F; UMBRICHT D; WOERNER M; FLEISCHHACKER WW; LIEBERMAN J
      THE PREVALENCE OF ACUTE EXTRAPYRAMIDAL SIGNS AND SYMPTOMS IN PATIENTSTREATED WITH CLOZAPINE, RISPERIDONE AND CONVENTIONAL ANTIPSYCHOTICS

      Schizophrenia research
    46. HUMMER M; KURZ M; KURZTHALER I; OBERBAUER H; MILLER C; FLEISCHHACKER WW
      HEPATOTOXICITY OF CLOZAPINE

      Journal of clinical psychopharmacology
    47. DEISENHAMMER EA; KEMMLER G; DECOL C; FLEISCHHACKER WW; HINTERHUBER H
      SUICIDES AND ATTEMPTED SUICIDES ON RAILWA YS IN AUSTRIA FROM 1990 TO 1994 - AN EXTENSION OF THE HYPOTHESIS OF TRANSMISSION OF SUICIDAL-BEHAVIOR VIA TELEVISION

      Nervenarzt
    48. FLEISCHHACKER WW; HUMMER M
      DRUG-TREATMENT AND SCHIZOPHRENIA IN THE 1990S - REPLY

      Drugs
    49. FLEISCHHACKER WW; HUMMER M
      DRUG-TREATMENT OF SCHIZOPHRENIA IN THE 1990S - ACHIEVEMENTS AND FUTURE POSSIBILITIES IN OPTIMIZING OUTCOMES

      Drugs
    50. SMALL JG; HIRSCH SR; ARVANITIS LA; MILLER BG; LINK CGG; MURPHY AL; BOWDEN CL; OBRIEN CP; STEINBOOK RM; WAGNER RL; PITTS WM; CRABTREE B; CORRIGAN MHN; LOHR JB; MILLER AL; ERESHEFSKY L; ANDERSON CB; KNESEVICH MA; ROTROSEN J; OWEN RR; KARSON CN; LINDENMAYER JP; PFEFFERBAUM A; FAUSTMAN WO; KECK PE; PATTERSON WM; RIESENBERG RA; GLADSON MB; KOLIN IS; BARNES TRE; SENSKY T; RICCIO M; FRANKS S; JOLLEY A; HALLSTROM C; BENNIE E; DARCOURT G; PATRIS M; DESILVA M; PATEL AG; FLEISCHHACKER WW; DIETZEL M; SEIFERTOVA D; VINAR O; FALTUS F; BITTER I; OZSVATH K; SHAW SH; MAHAPATRA SN; SZULECKA TK; SUNDARARAJAN K; CREAVEN F; LYNCH J; KLIESER E; COOPER SJ; ASCHAUER H
      QUETIAPINE IN PATIENTS WITH SCHIZOPHRENIA - A HIGH-DOSE AND LOW-DOSE DOUBLE-BLIND COMPARISON WITH PLACEBO

      Archives of general psychiatry
    51. KURZTHALER I; HUMMER M; KOHL C; MILLER C; FLEISCHHACKER WW
      PROPRANOLOL TREATMENT OF OLANZAPINE-INDUCED AKATHISIA

      The American journal of psychiatry
    52. FLEISCHHACKER WW
      RECOGNITION, AVOIDANCE AND MANAGEMENT OF DRUG-INDUCED EXTRAPYRAMIDAL SYNDROMES - A THERAPEUTIC CHALLENGE IN PATIENTS WITH SCHIZOPHRENIA - ASEMINAR-IN-PRINT - FOREWORD

      CNS DRUGS
    53. HUMMER M; FLEISCHHACKER WW
      COMPLIANCE AND OUTCOME IN PATIENTS TREATED WITH ANTIPSYCHOTICS - THE IMPACT OF EXTRAPYRAMIDAL SYNDROMES

      CNS DRUGS
    54. CASEY DE; FLEISCHHACKER WW; REMINGTON G
      QUESTIONS AND ANSWERS

      CNS DRUGS
    55. FLEISCHHACKER WW; LINKZ CGG; HURST BC
      ICI-204636 (SEROQUEL) - A PUTATIVE NEW ATYPICAL ANTIPSYCHOTIC - RESULTS FROM PHASE-III TRIALS

      Schizophrenia research
    56. KURZ M; HUMMER M; OBERBAUER H; KURZTHALER I; FLEISCHHACKER WW
      TERMINATION OF CLOZAPINE TREATMENT

      Schizophrenia research
    57. HUMMER M; OBERBAUER H; KURZ M; KURZTHALER I; SCHNEGG G; FLEISCHHACKER WW
      HEPATOTOXICITY OF CLOZAPINE

      Schizophrenia research
    58. WHITWORTH AB; HONEDER M; KREMSER C; SPERNER B; FELBER S; STUPPAECK CH; FLEISCHHACKER WW
      AN MRI VOLUMETRIC STUDY IN SCHIZOPHRENIC-PATIENTS

      Schizophrenia research
    59. LIEBERMAN JA; FLEISCHHACKER WW
      CURRENT ISSUES IN THE DEVELOPMENT OF ATYPICAL ANTIPSYCHOTIC-DRUGS - INTRODUCTION

      British Journal of Psychiatry
    60. MEISE U; FLEISCHHACKER WW
      PERSPECTIVES ON TREATMENT NEEDS IN SCHIZOPHRENIA

      British Journal of Psychiatry
    61. MILLER C; KIRCHMAIR R; TROGER J; SARIA A; FLEISCHHACKER WW; FISCHERCOLBRIE R; BENZER A; WINKLER H
      CSF OF NEUROLEPTIC-NAIVE FIRST-EPISODE SCHIZOPHRENIC-PATIENTS - LEVELS OF BIOGENIC-AMINES, SUBSTANCE-P, AND PEPTIDES DERIVED FROM CHROMOGRANIN-A (GE-25) AND SECRETOGRANIN-II (SECRETONEURIN)

      Biological psychiatry
    62. HUMMER M; SPERNERUNTERWEGER B; KEMMLER G; FALK M; KURZ M; OBERBAUER H; FLEISCHHACKER WW
      DOES EOSINOPHILIA PREDICT CLOZAPINE-INDUCED NEUTROPENIA

      Psychopharmacology
    63. HUMMER M; KEMMLER G; KURZ M; KURZTHALER I; OBERBAUER H; FLEISCHHACKER WW
      WEIGHT-GAIN INDUCED BY CLOZAPINE

      European neuropsychopharmacology
    64. MILLER CH; KIRCHMAIR R; SARIA A; FLEISCHHACKER WW; WINKLER H
      CONCENTRATIONS OF SECRETONEURIN AND CHROMOGRANIN-A IMMUNOREACTIVITIESIN THE CEREBROSPINAL-FLUID OF SCHIZOPHRENIC-PATIENTS

      Schizophrenia research
    65. WHITWORTH AB; HONEDER M; KREMSER C; SPERNER B; FELBER S; STUPPAECK CH; FLEISCHHACKER WW
      MRI-MEASUREMENTS IN SCHIZOPHRENICS

      Schizophrenia research
    66. HUMMER M; KURZ M; KEMMLER J; KURZTHALER I; OBERBAUER H; FLEISCHHACKER WW
      CLOZAPINE IN THE TREATMENT OF FIRST-EPISODE AND MULTI-EPISODE SCHIZOPHRENIC-PATIENTS

      Schizophrenia research
    67. STUPPAECK CH; MILLER CH; EHRMANN H; FLEISCHHACKER WW; FELBER S; POEWE W
      AKATHISIA INDUCED BY NECROSIS OF THE BASAL GANGLIA AFTER CARBON-MONOXIDE INTOXICATION

      Movement disorders
    68. WHITWORTH AB; FLEISCHHACKER WW
      ADVERSE-EFFECTS OF ANTIPSYCHOTIC-DRUGS

      International clinical psychopharmacology
    69. POLLACK S; LIEBERMAN JA; FLEISCHHACKER WW; BORENSTEIN M; SAFFERMAN AZ; HUMMER M; KURZ M
      A COMPARISON OF EUROPEAN AND AMERICAN DOSING REGIMENS OF SCHIZOPHRENIC-PATIENTS ON CLOZAPINE - EFFICACY AND SIDE-EFFECTS

      Psychopharmacology bulletin
    70. MILLER CH; SIMIONI I; OBERBAUER H; SCHWITZER J; BARNAS C; KULHANEK F; BOISSEL KE; MEISE U; HINTERHUBER H; FLEISCHHACKER WW
      TARDIVE-DYSKINESIA PREVALENCE RATES DURING A 10-YEAR FOLLOW-UP

      The Journal of nervous and mental disease
    71. WHITWORTH AB; FLEISCHHACKER WW
      STEROID-INDUCED PSYCHOSIS

      Hautarzt
    72. KURZ M; HUMMER M; KURZTHALER I; OBERBAUER H; FLEISCHHACKER WW
      EFFICACY OF MEDIUM-DOSE CLOZAPINE FOR TREATMENT-RESISTANT SCHIZOPHRENIA

      The American journal of psychiatry
    73. FLEISCHHACKER WW
      NEW DRUGS FOR THE TREATMENT OF SCHIZOPHRENIC-PATIENTS

      Acta psychiatrica Scandinavica
    74. DENBOER JA; VANMEGEN HJGM; FLEISCHHACKER WW; LOUWERENS JW; SLAAP BR; WESTENBERG HGM; BURROWS GD; SRIVASTAVA ON
      DIFFERENTIAL-EFFECTS OF THE D1-DA RECEPTOR ANTAGONIST SCH139166 ON POSITIVE AND NEGATIVE SYMPTOMS OF SCHIZOPHRENIA

      Psychopharmacology
    75. KURZ M; HUMMER M; OBERBAUER H; FLEISCHHACKER WW
      EXTRAPYRAMIDAL SIDE-EFFECTS OF CLOZAPINE AND HALOPERIDOL

      Psychopharmacology
    76. MEISE U; ROSSLER W; FLEISCHHACKER WW
      OUTPATIENT CARE IN SCHIZOPHRENIA - TREATMENT CONSIDERATIONS

      CNS DRUGS
    77. STUPPAECK CH; BARNAS C; FALK M; GUENTHER V; HUMMER M; OBERBAUER H; PYCHA R; WHITWORTH AB; FLEISCHHACKER WW
      ASSESSMENT OF THE ALCOHOL-WITHDRAWAL SYNDROME - VALIDITY AND RELIABILITY OF THE TRANSLATED AND MODIFIED CLINICAL INSTITUTE WITHDRAWAL ASSESSMENT FOR ALCOHOL SCALE (CIWA-A)

      Addiction
    78. MEISE U; KURZ M; FLEISCHHACKER WW
      ANTIPSYCHOTIC MAINTENANCE TREATMENT OF SCHIZOPHRENIA-PATIENTS - IS THERE A CONSENSUS

      Schizophrenia bulletin
    79. STUPPAECK CH; GERETSEGGER C; WHITWORTH AB; SCHUBERT H; PLATZ T; KONIG P; HINTERHUBER H; FLEISCHHACKER WW
      A MULTICENTER DOUBLE-BLIND TRIAL OF PAROXETINE VERSUS AMITRIPTYLINE IN DEPRESSED INPATIENTS

      Journal of clinical psychopharmacology
    80. FLEISCHHACKER WW; HUMMER M; KURZ M; KURZTHALER I; LIEBERMAN JA; POLLACK S; SAFFERMAN AZ; KANE JM
      CLOZAPINE DOSE IN THE UNITED-STATES AND EUROPE - IMPLICATIONS FOR THERAPEUTIC AND ADVERSE-EFFECTS

      The Journal of clinical psychiatry
    81. STUPPAECK CH; BARNAS C; SCHWITZER J; FLEISCHHACKER WW
      CARBAMAZEPINE IN THE PROPHYLAXIS OF MAJOR DEPRESSION - A 5-YEAR FOLLOW-UP

      The Journal of clinical psychiatry
    82. HUMMER M; KURZ M; BARNAS C; SARIA A; FLEISCHHACKER WW
      CLOZAPINE-INDUCED TRANSIENT WHITE BLOOD-COUNT DISORDERS

      The Journal of clinical psychiatry
    83. BARNAS C; BERGANT A; HUMMER M; SARIA A; FLEISCHHACKER WW
      CLOZAPINE CONCENTRATIONS IN MATERNAL AND FETAL PLASMA, AMNIOTIC-FLUID, AND BREAST-MILK

      The American journal of psychiatry
    84. FLEISCHHACKER WW; MEISE U; GUNTHER V; KURZ M
      COMPLIANCE WITH ANTIPSYCHOTIC DRUG-TREATMENT - INFLUENCE OF SIDE-EFFECTS

      Acta psychiatrica Scandinavica
    85. MOLLER HJ; VANPRAAG HM; AUFDEMBRINKE B; BAILEY P; BARNES TRE; BECK J; BENTSEN H; EICH FX; FARROW L; FLEISCHHACKER WW; GERLACH J; GRAFFORD K; HENTSCHEL B; HERTKORN A; HEYLEN S; LECRUBIER Y; LEONARD JP; MCKENNA P; MAIER W; PEDERSEN V; RAPPARD A; REIN W; RYAN J; NIELSEN MS; STIEGLITZ RD; WEGENER G; WILSON J
      NEGATIVE SYMPTOMS IN SCHIZOPHRENIA - CONSIDERATIONS FOR CLINICAL-TRIALS

      Psychopharmacology
    86. HARING C; NEUDORFER C; SCHWITZER J; HUMMER M; SARIA A; HINTERHUBER H; FLEISCHHACKER WW
      EEG ALTERATIONS IN PATIENTS TREATED WITH CLOZAPINE IN RELATION TO PLASMA-LEVELS

      Psychopharmacology
    87. MEISE U; KURZ M; FLEISCHHACKER WW
      CLOZAPINE FOR THE RELAPSE PREVENTION IN S CHIZOPHRENIA

      Fortschritte der Neurologie, Psychiatrie
    88. STUPPAECK C; BARNAS C; SCHWITZER J; FLEISCHHACKER WW
      THE ROLE OF CARBAMAZEPINE IN THE PROPHYLAXIS OF UNIPOLAR DEPRESSION

      Neuropsychobiology
    89. PYCHA R; MILLER C; BARNAS C; HUMMER M; STUPPACK C; WHITWORTH A; FLEISCHHACKER WW
      INTRAVENOUS FLUNITRAZEPAM IN THE TREATMENT OF ALCOHOL-WITHDRAWAL DELIRIUM

      Alcoholism, clinical and experimental research
    90. STUPPAECK CH; WHITWORTH AB; FLEISCHHACKER WW
      ABUSE POTENTIAL OF CARBAMAZEPINE

      The Journal of nervous and mental disease
    91. FLEISCHHACKER WW; MILLER CH; BARNAS C; BERGMANN K; PEROVICH R; ALVIR JMJ; LIEBERMAN JA; KANE JM
      THE EFFECT OF ACTIVATION PROCEDURES ON NEUROLEPTIC-INDUCED AKATHISIA

      British Journal of Psychiatry
    92. SPERNERUNTERWEGER B; GAGGL S; FLEISCHHACKER WW; BARNAS C; HEROLD M; GEISSLER D
      EFFECTS OF CLOZAPINE ON HEMATOPOIESIS AND THE CYTOKINE SYSTEM

      Biological psychiatry
    93. FLEISCHHACKER WW; LEVINE RA; LIEBERMAN JA; POLLACK S; JOHNS CA; RICHARDSON MA
      NEOPTERIN AND BIOPTERIN CSF LEVELS IN TARDIVE-DYSKINESIA AFTER CLOZAPINE TREATMENT

      Biological psychiatry
    94. FELBER SR; PYCHA R; HUMMER M; AICHNER FT; FLEISCHHACKER WW
      LOCALIZED PROTON AND PHOSPHORUS MAGNETIC-RESONANCE SPECTROSCOPY FOLLOWING ELECTROCONVULSIVE-THERAPY

      Biological psychiatry
    95. SCHWITZER J; NEUDORFER C; FLEISCHHACKER WW
      SEASONAL BULIMIA TREATED WITH FLUOXETINE AND PHOTOTHERAPY

      The American journal of psychiatry
    96. BARNAS C; WHITWORTH AB; FLEISCHHACKER WW
      ARE PATTERNS OF BENZODIAZEPINE USE PREDICTABLE - A FOLLOW-UP-STUDY OFBENZODIAZEPINE USERS

      Psychopharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/12/19 alle ore 15:14:45